<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"
        xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd http://www.google.com/schemas/sitemap-news/0.9 http://www.google.com/schemas/sitemap-news/0.9/sitemap-news.xsd http://www.google.com/schemas/sitemap-image/1.1 https://www.google.com/schemas/sitemap-image/1.1/sitemap-image.xsd">
    <url>
      <loc>https://idahohealthcarehub.com/article/904092950-organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-2026-financial-results-on-may-7-2026</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:30:00+00:00</news:publication_date>
        <news:title>Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/9c2f551f-b7b2-403a-bf43-78f1889401e5/small/organogenesis-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://idahohealthcarehub.com/article/904092960-medicus-pharma-submits-optimized-phase-2-study-protocol-to-u-s-fda-for-teverelix-in-acute-urinary-retention</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:30:00+00:00</news:publication_date>
        <news:title>Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/0f5af1d1-dfba-4810-baac-d1922c0558c1/small/medicus-logo-rgb-05-aspect-1500px-globe-newswire-2-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://idahohealthcarehub.com/article/904092976-kraig-biocraft-laboratories-shatters-production-record-delivering-over-1-3-metric-tons-of-spider-silk-cocoons-in-a-single-month-a-5x-increase-over</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:05:00+00:00</news:publication_date>
        <news:title>Kraig Biocraft Laboratories Shatters Production Record, Delivering Over 1.3 Metric Tons of Spider Silk Cocoons in a Single Month, A 5X Increase Over Previous High</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/bd9626d2-4b5e-4f55-8b54-c8300fa5bef5/medium/bam1-recombinant-spider-silk-cocoons.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://idahohealthcarehub.com/article/904089915-invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:01:00+00:00</news:publication_date>
        <news:title>Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/7bf12f50-1073-4ce7-81ac-89426c07add3/small/untitled-design-2-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://idahohealthcarehub.com/article/904089912-stipple-bio-emerges-from-stealth-with-oversubscribed-100-million-series-a-financing-to-advance-stp-100-into-early-clinical-studies-and-advance-a</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/96c458bd-cad2-4343-89d4-8c60bcfde0a5/small/stipple-no-name-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://idahohealthcarehub.com/article/904089917-biocryst-appoints-sandeep-m-menon-chief-research-and-development-officer</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/8b033909-1a3c-4811-b07b-fe03b12e00d2/small/biocryst-primarylogo-r-2c-rgb-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://idahohealthcarehub.com/article/904089923-sagimet-biosciences-announces-poster-and-oral-presentations-at-the-fueling-mash-metabolic-drivers-and-inflammatory-crosstalk-keystone-symposium-and</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/e944daed-3f71-402b-bb23-82149e5c0d26/small/sagimet-logo-for-light-bg-fin-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://idahohealthcarehub.com/article/904089924-immunocore-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference  </news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml-eu.globenewswire.com/media/bcaafaab-2536-4b4b-899c-9913925b6e4b/small/immunocore-logo-2018.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://idahohealthcarehub.com/article/904089932-agios-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-april-29-at-8-00-a-m-et</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/c7d64dad-71c8-47cc-a58d-c93a49ce8f01/small/agios-2021-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://idahohealthcarehub.com/article/904089955-opus-genetics-solidifies-leadership-position-in-gene-therapy-development-for-inherited-retinal-diseases-with-strategic-long-term-financing-by-oberland</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/468baef1-3b2d-4353-a17e-cb41b45ee6ef/small/opus-rgb-r-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://idahohealthcarehub.com/article/904089957-nrx-pharmaceuticals-nasdaq-nrxp-announces-fda-labeling-alignment-for-nrx-s-preservative-free-ketamine-application</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://idahohealthcarehub.com/article/904089969-sharps-technology-reports-2025-year-end-results-and-highlights-continued-execution-of-solana-treasury-strategy</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>Sharps Technology Reports 2025 Year-End Results and Highlights Continued Execution of Solana Treasury Strategy</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/7e8b9bfa-42f5-446c-932a-41a01c25ed6b/small/sharps-technology-nasdaq-stss-white-background-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://idahohealthcarehub.com/article/904089975-neumora-therapeutics-to-participate-in-25th-annual-needham-virtual-healthcare-conference</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/48256578-6cd3-4332-bf9b-2f52cfa248b7/small/neumora-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://idahohealthcarehub.com/article/904086918-beacon-biosignals-upsizes-series-b-financing-to-over-97-million</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T10:30:00+00:00</news:publication_date>
        <news:title>Beacon Biosignals Upsizes Series B Financing to Over $97 Million</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/0485bb01-d362-473e-8fae-a6cab3b804aa/small/beacon-logo-inline-1-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://idahohealthcarehub.com/article/904084259-profusa-expands-into-multi-billion-dollar-precision-diagnostics-market-with-30m-letter-of-intent-for-a-panomics-platform</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T10:00:00+00:00</news:publication_date>
        <news:title>Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform </news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/a8137a61-b858-48da-9e47-1f1bf8f6ddba/small/profusa-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://idahohealthcarehub.com/article/903833852-medvi-quad-claims-evaluated-real-online-doctor-approval-ed-medication-for-men-s-sexual-performance</loc>
      <news:news>
        <news:publication>
          <news:name>Idaho Healthcare Hub</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-04T20:05:45+00:00</news:publication_date>
        <news:title>MEDVi QUAD Claims Evaluated: Real Online Doctor-Approval ED Medication for Men&#39;s Sexual Performance</news:title>
      </news:news>
        <image:image>
          <image:loc>https://zingfast.com/wp-content/uploads/2026/04/MEDVi-QUAD.jpg</image:loc>
        </image:image>
    </url>
</urlset>
